High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)

Tam Nguyen Truong, Didier Laureillard, Karine Lacombe, Huong Duong Thi, Phuc Pham Thi Hanh, Lien Truong Thi Xuan, Nga Chu Thi, Anh Luong Que, Vinh Vu Hai, Nicolas Nagot, Edouard Tuaillon, Stéphanie Dominguez, Maud Lemoine, Tam Nguyen Truong, Didier Laureillard, Karine Lacombe, Huong Duong Thi, Phuc Pham Thi Hanh, Lien Truong Thi Xuan, Nga Chu Thi, Anh Luong Que, Vinh Vu Hai, Nicolas Nagot, Edouard Tuaillon, Stéphanie Dominguez, Maud Lemoine

Abstract

Rationale and aims: Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northern Vietnam.

Methods: A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated adults with positive HCV serology completed a standardised epidemiological questionnaire and had a comprehensive liver assessment including hepatic elastography (Fibroscan®, Echosens).

Results: From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7-39.6) years, median CD4 count: 504 (361-624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA (median 6.19 (4.95-6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b (69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosis ≥F2 including 24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis, excessive alcohol consumption, estimated time duration from HCV infection, nevirapine and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibrosis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multivariate analysis. Using Fibroscan® as a gold standard, the high thresholds of AST-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs = 0.93, 95%CI: 0.86-0.99 and 0.96 (0.92-0.99), respectively).

Conclusion: In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flowchart of the study population.
Fig 1. Flowchart of the study population.
Fig 2. Performance of APRI in diagnosing…
Fig 2. Performance of APRI in diagnosing extensive fibrosis (F3) and cirrhosis using a high threshold (APRI > 2) (Fig 1A) and a low threshold (APRI>1) (Fig 1B).
Fig 3. Performance of FIB-4 in diagnosing…
Fig 3. Performance of FIB-4 in diagnosing extensive fibrosis (F3) using a high threshold (FIB-4 > 3.25) (Fig 3A) and a low threshold (FIB-4 > 1.25) (Fig 3B).

References

    1. UNAIDS. Last accessed 3rd of June 2014. 2013.
    1. WHO;. Guidelines for the screening, care and treatment of persons with hepatitis C infection Accessed 18t March 2015. 2014.
    1. Joshi D O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198–209. 10.1016/S0140-6736(10)62001-6
    1. Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, et al. Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. Journal of gastroenterology and hepatology. 2012;27(2):238–47. 10.1111/j.1440-1746.2011.06974.x .
    1. Viet nam HIV/AIDS ESTIMATES AND PROJECTIONS 2007–2012. MINISTRY OF HEALTH–VIET NAM ADMINISTRATION OF HIV/AIDS CONTROL.
    1. Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, et al. Vietnamese community screening for hepatitis B virus and hepatitis C virus. Journal of viral hepatitis. 2011;18(1):70–6. 10.1111/j.1365-2893.2010.01278.x .
    1. Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012;11(5):311–20. Epub 2012/07/26. 10.1177/1545109712453939 .
    1. Clatts MC, Colón-López V, Giang LM, Goldsamt LA. Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection. Journal of Urban Health: Bulletin of the New York Academy of Medicine 2009;87(2). 10.1007/s11524-009-9417-9
    1. Quan VM, Go VF, Nam le V, Bergenstrom A, Thuoc NP, Zenilman J, et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care. 2009;21(1):7–16. 10.1080/09540120802017610
    1. Zhang L, Celentano DD, Le Minh N, Latkin CA, Mehta SH, Frangakis C, et al. Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam. European journal of gastroenterology & hepatology. 2015;27(5):550–6. 10.1097/MEG.0000000000000321
    1. Vietnam AIDS response progress report 2014. National committee for AIDS, drugs and prostitution prevention and control. Hanoi.
    1. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012;54(10):1465–72. Epub 2012/03/21. doi: cis227 [pii] 10.1093/cid/cis227 .
    1. Lemoine M, Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Seminars in liver disease. 2014;34(1):89–97. Epub 2014/05/02. 10.1055/s-0034-1371082 .
    1. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. The New England journal of medicine. 2014;370(20):1869–71. 10.1056/NEJMp1400160 .
    1. Lemoine M, Thursz M, Njie R, Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver international: official journal of the International Association for the Study of the Liver. 2014;34(1):12–5. Epub 2013/09/04. 10.1111/liv.12283 .
    1. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13. Epub 2003/12/31. .
    1. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182–91. 10.1002/hep.25993 .
    1. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58(1):65–72. Epub 2013/03/01. 10.1002/hep.26343 .
    1. Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Alimentary pharmacology & therapeutics. 2014;39(2):188–96. Epub 2013/12/07. 10.1111/apt.12561 .
    1. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50. Epub 2005/02/03. .
    1. Nacro B, Zoure E, Hien H, Tamboura H, Rouet F, Ouiminga A, et al. Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. Bulletin of the World Health Organization. 2011;89(6):451–8. 10.2471/BLT.10.081646
    1. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver international: official journal of the International Association for the Study of the Liver. 2013;33(1):62–71. 10.1111/liv.12003 .
    1. Huy BV, Vernavong K, Kinh NV. HBV and HCV Coinfection among HIV/AIDS Patients in the National Hospital of Tropical Diseases, Vietnam. AIDS research and treatment. 2014;2014:581021 10.1155/2014/581021
    1. Ye S, Pang L, Wang X, Liu Z. Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia. Current HIV/AIDS reports. 2014;11(2):128–33. 10.1007/s11904-014-0206-z .
    1. Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, et al. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. Journal of gastroenterology and hepatology. 2014;29(9):1706–14. 10.1111/jgh.12613 .
    1. Carton JA, Collazos J, de la Fuente B, Garcia-Alcalde ML, Suarez-Zarracina T, Rodriguez-Guardado A, et al. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antiviral therapy. 2011;16(1):27–35. 10.3851/IMP1708 .
    1. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(7):963–72. .
    1. Macias J, Recio E, Vispo E, Rivero A, Lopez-Cortes LF, Rios MJ, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. Journal of hepatology. 2008;49(6):916–22. 10.1016/j.jhep.2008.07.031 .
    1. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study—ANRS HC02. Journal of hepatology. 2008;48(5):765–73. 10.1016/j.jhep.2008.01.025 .
    1. Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in Hai Phong, Vietnam: a qualitative analysis. BMC public health. 2015;15:32 10.1186/s12889-015-1404-3
    1. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. The Lancet Infectious diseases. 2015;15(1):36–45. 10.1016/S1473-3099(14)71045-X .
    1. Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, et al. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol. 2009;27(2–3):153–60. .
    1. Tanimoto T, Nguyen HC, Ishizaki A, Chung PT, Hoang TT, Nguyen VT, et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. Journal of medical virology. 2010;82(8):1355–63. 10.1002/jmv.21787
    1. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. Journal of hepatology. 2011;54(4):650–9. 10.1016/j.jhep.2010.07.033 .
    1. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41(2):175–9. .
    1. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of hepatology. 2014;60(2):392–420. 10.1016/j.jhep.2013.11.003 .
    1. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, et al. How to optimize HCV treatment impact on life years saved in resource-constrained countries. Hepatology. 2015. 10.1002/hep.27691 .
    1. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of viral hepatitis. 2008;15(10):747–52. 10.1111/j.1365-2893.2008.01010.x .
    1. Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug and alcohol dependence. 2010;109(1–3):248–51. 10.1016/j.drugalcdep.2010.01.009 .
    1. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. Journal of viral hepatitis. 2015;22(4):399–408. 10.1111/jvh.12338
    1. Hellard ME, Jenkinson R, Higgs P, Stoove MA, Sacks-Davis R, Gold J, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. The Medical journal of Australia. 2012;196(10):638–41. .
    1. Huu Bich T, Thi Quynh Nga P, Ngoc Quang L, Van Minh H, Ng N, Juvekar S, et al. Patterns of alcohol consumption in diverse rural populations in the Asian region. Global health action. 2009;2 10.3402/gha.v2i0.2017
    1. Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. Journal of gastroenterology. 2009;44(5):439–46. Epub 2009/03/25. 10.1007/s00535-009-0017-y .
    1. World Health Organization, Global Hepatitis Programme, Global partners. Last accessed 10 July 2015. 2014.
    1. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver international: official journal of the International Association for the Study of the Liver. 2013;33 Suppl 1:68–79. Epub 2013/01/11. 10.1111/liv.12063 .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit